Lirentelimab (AK002) ( DrugBank: Lirentelimab )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 98 | 好酸球性消化管疾患 | 3 |
98. 好酸球性消化管疾患
臨床試験数 : 172 / 薬物数 : 149 - (DrugBank : 39) / 標的遺伝子数 : 38 - 標的パスウェイ数 : 135
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04856891 (ClinicalTrials.gov) | May 20, 2021 | 20/4/2021 | A Study of Lirentelimab (AK002) in Patients With Active Eosinophilic Duodenitis | A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of AK002 in Patients With Moderately to Severely Active Eosinophilic Duodenitis Who Have an Inadequate Response With, Lost Response to, or Were Intolerant to Standard Therapies | Eosinophilic Duodenitis;Eosinophilic Gastroenteritis | Drug: AK002;Other: Placebo | Allakos, Inc. | NULL | Active, not recruiting | 18 Years | 80 Years | All | 94 | Phase 3 | United States |
| 2 | NCT04322708 (ClinicalTrials.gov) | July 6, 2020 | 24/3/2020 | A Study of Lirentelimab (AK002) in Patients With Active Eosinophilic Esophagitis | A Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Lirentelimab (AK002) in Adult and Adolescent Patients With Active Eosinophilic Esophagitis | Eosinophilic Esophagitis | Other: Placebo;Drug: lirentelimab (AK002) | Allakos, Inc. | NULL | Active, not recruiting | 12 Years | 80 Years | All | 277 | Phase 2/Phase 3 | United States;Australia;Netherlands |
| 3 | NCT04322604 (ClinicalTrials.gov) | June 18, 2020 | 24/3/2020 | A Study to Assess AK002 in Eosinophilic Gastritis and/or Eosinophilic Duodenitis (Formerly Referred to as Eosinophilic Gastroenteritis) | A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of AK002 in Patients With Moderately to Severely Active Eosinophilic Gastritis and/or Eosinophilic Duodenitis (Formerly Referred to as Eosinophilic Gastroenteritis) | Eosinophilic Gastritis;Eosinophilic Duodenitis | Drug: lirentelimab (AK002);Other: Placebo | Allakos, Inc. | NULL | Active, not recruiting | 18 Years | 80 Years | All | 180 | Phase 3 | United States |